Genetic Counseling & Ethics in Neurogenetics

Genetic counseling is often misread as the act of explaining a test result. Its formal definition — helping people understand and adapt to the medical, psychological, and familial implications of genetic disease — deliberately puts adaptation alongside understanding. The information is necessary but not sufficient; the work is helping a person integrate that information into a life already in progress.

Why non-directiveness, and what it is not

The field's commitment to non-directiveness is a historical reaction against the eugenics era, when 'genetic advice' meant steering reproduction toward state-defined goals. Modern counseling instead protects autonomy: the counselor supplies balanced information and helps clarify the patient's own values, but does not tell them what to choose. Non-directiveness is not withholding an opinion when asked a factual question, nor pretending all outcomes are equivalent. It means the decision — to test, to continue a pregnancy, to inform a relative — belongs to the patient, because they alone bear its consequences.

Pre-test counseling sets up everything downstream

• A three-generation pedigree is diagnostic reasoning in visual form: it reveals inheritance pattern, identifies the most-informative person to test first, flags consanguinity (raising prior probability of recessive disease), and surfaces at-risk relatives who may need cascade testing later.
• Test selection is a deliberate trade-off, not a default to the broadest test. A targeted panel or repeat-expansion assay gives a cleaner yes/no with fewer incidental findings; exome/genome cast a wider net but generate more VUS and secondary findings — each of which becomes its own counseling burden.
• The single most important pre-test task is anticipatory guidance: walking through the full menu of outcomes before the sample is drawn — a definitive diagnosis, a VUS that resolves nothing, a secondary finding in an ACMG SF gene, a truly negative result that still leaves residual risk, and unexpected findings such as misattributed parentage. A family that has rehearsed these possibilities makes a more autonomous choice and is far less destabilized by an ambiguous report.

Informed consent is the documented product of that conversation: purpose, the result types above, test limitations, implications for blood relatives, insurance considerations, and — explicitly — the right to decline any or all of it.

Post-test counseling is where adaptation actually happens: disclosure in a supportive setting, correlation of the variant to the phenotype, psychosocial support, specialist coordination, and — for the common uninformative result — an honest account of residual risk plus a concrete plan for re-analysis, since today's VUS may be reclassified as the evidence base grows.

Predictive testing is fundamentally different from diagnostic testing: the person in front of you is well. There is no symptom to relieve, no treatment to start. The result changes only what they know about their future — and knowledge, once given, cannot be returned. That asymmetry is why predictive testing has its own protocol rather than being treated as just another lab order.

Why Huntington disease became the paradigm

HD is the worst-case template, and that is precisely why its protocol is so cautious: it is autosomal dominant with near-complete penetrance at CAG ≥40, has a predictable adult onset, and — historically — no disease-modifying treatment. A positive result therefore delivers near-certainty of an untreatable fatal disease while the person is still healthy. The international guidelines built around this scenario (MacLeod et al. 2013) require ≥2 pre-test counseling sessions separated by a deliberate cooling-off period, formal psychological assessment screening for depression and suicidality, an identified support person, and confirmation that no minor is being tested for an adult-onset condition. Results are never given by phone or to third parties without consent. Each step exists to slow an irreversible decision and to ensure the person is psychologically prepared for either answer.

The right not to know is a real and protected interest

Autonomy includes the freedom to not learn one's genetic future, and this right can collide with a relative's wish to test. The classic conflict: a grandchild's positive HD result mathematically proves that an intervening parent — who chose not to know — also carries the expansion. Exclusion testing resolves this by using linkage to ask only whether the at-risk haplotype came from the affected grandparent, quantifying the grandchild's risk without ever disclosing the parent's status. It is an elegant illustration that genetic information is inherently shared, never wholly one person's own.

The insurance gap patients rarely anticipate

In the US, GINA (2008) bars genetic discrimination by health insurers and employers — but its protection stops there. Life, disability, and long-term-care insurers may legally underwrite on a positive predictive result, and an HD expansion can be used to deny a life policy. Counseling people to secure these policies before testing is concrete, actionable advice that protects them in a way the law does not.

Both results can harm

Roughly 10% of HD predictive-testing recipients have clinically significant adverse reactions. Crucially, distress is not confined to bad news: a negative result can bring survivor guilt, the loss of an identity organized for years around being at-risk, and the disorientation of an unplanned future — which is why post-result support is offered regardless of the answer.

Pediatric testing turns on a question no other patient group raises: the person being tested cannot consent, yet the result follows them for life. The guiding rule is therefore not 'can we test?' but 'does this child benefit from knowing now?' — with the child's future autonomy treated as a real asset to be protected, not a formality to be waived.

The deciding question: childhood medical actionability

Testing a child is appropriate when the result changes management during childhood. The benefit is concrete and the autonomy cost is justified by it:

• TSC: molecular confirmation triggers a defined surveillance schedule (brain MRI, renal ultrasound, echocardiography, ophthalmology) that catches SEGAs, renal angiomyolipomas, and cardiac rhabdomyomas before they cause harm. Knowing the diagnosis early demonstrably improves outcomes.
• SMA: this is the strongest case, because the therapeutic window is biological, not bureaucratic. Motor neurons lost before treatment do not return, so nusinersen, onasemnogene abeparvovec, and risdiplam are dramatically more effective presymptomatically — every day of delay can cost irreplaceable neurons. See the Genetic Neuromuscular Disorders module.

*Why we deliberately don't test for adult-onset conditions*

For a condition like HD with no childhood intervention, ACMG and AAP recommend deferring until the individual can consent for themselves. The reasoning is symmetrical with the predictive-testing protocol: testing the child captures no medical benefit while permanently foreclosing their right to decide whether they ever want to know. Parental authority to consent for medical care does not extend to surrendering a competency that belongs to the future adult.

Newborn screening makes this a population-scale problem

NBS shifts these decisions from individual families to public-health policy. SMA was added to the US RUSP in 2018 and is now screened in all 50 states — a genuine success, because it operationalizes presymptomatic SMA treatment at scale. But each candidate condition reopens the actionability debate: should the panel include disorders with variable expressivity (where a positive screen may never become disease) or uncertain treatment efficacy (where early knowledge brings anxiety without clear benefit)? The threshold for inclusion is an ethical judgment, not just a technical one.

Genome-wide newborn screening pushes the tension to its limit

Pilots such as BabySeq, GUARDIAN, and the UK Newborn Genomes Programme could flag hundreds of treatable conditions from a single sample — but at the cost of generating VUS in healthy infants, occasionally surfacing adult-onset risks the child never consented to learn, and creating the 'patient-in-waiting': a well child medicalized by a probabilistic result, subjected to surveillance and parental anxiety for a disease that may never arrive.

Once you sequence an exome or genome, you have, in effect, read genes you never intended to look at. Some of those genes carry pathogenic variants that — independent of why the test was ordered — predict a serious but preventable disease. The ACMG's response is the concept of opportunistic screening: since the data already exist, deliberately mine a curated list of genes and report back the ones where acting now can avert harm. A variant found this way is a secondary finding (SF) — sought on purpose, but unrelated to the indication.

The list is defined by actionability, not by severity or interest

• Current version: ACMG SF v3.3 (2025), 84 genes (Miller et al. 2023 describe the framework and its periodic, roughly annual revision).
• The inclusion bar is narrow and specific: a gene earns a place only when an established intervention can prevent or substantially reduce morbidity and mortality. That is why the list is dominated by hereditary cancer (BRCA1/BRCA2, the Lynch mismatch-repair genes, TP53), inherited cardiovascular disease (cardiomyopathies, long-QT and other arrhythmias, aortopathies), malignant hyperthermia (RYR1, CACNA1S), and familial hypercholesterolemia. A devastating but unactionable finding does not qualify — there is no benefit to offset the burden of knowing.
• Only P/LP variants in listed genes count. A VUS is never reported as an SF (acting on uncertain evidence would cause net harm), and a pathogenic variant in a gene off the list is not sought.

Consent is a duty to offer, not a default to report

• ACMG frames SF as something the patient must be offered and may decline (opt out) at consent — the patient's right not to know applies here just as it does in predictive testing.
• Laboratories operationalize this differently; many require an explicit opt-in rather than honoring a true opt-out default, so SF are not automatically returned everywhere.
• The practical consequence for the ordering clinician is non-negotiable: offer the choice and document the decision before the sample is sent. Discovering after the fact that a patient was never asked is both an ethical and a medico-legal failure.

The pediatric tension — and why ACMG accepts it

• The SF list is applied regardless of age. An adult-onset finding such as a pathogenic BRCA variant can therefore be returned from a child's exome ordered for an unrelated reason like epilepsy.
• This openly contradicts the rule, two sections up, that we defer predictive testing for adult-onset conditions in minors. ACMG accepts the contradiction on two grounds: the finding is incidental (ascertained while pursuing the child's own care, not by targeted predictive testing of the child), and it carries direct benefit to the family — a BRCA variant in the child usually traces to an at-risk parent who can act today. The justification is genuinely contested, the child's best interest is still weighed case by case, and reasonable experts disagree.

When an SF returns the response is procedural: confirm the variant on an independent sample, refer to the relevant specialty (oncology, cardiology, genetics), offer cascade testing to at-risk relatives, and start guideline-based surveillance. The point of the whole enterprise is realized only at this step — a finding nobody was looking for becomes a prevented cancer or a recognized arrhythmia.

The complete ACMG SF v3.3 list (84 genes)

Only pathogenic or likely-pathogenic variants in these genes are reported as secondary findings. The three genes added in v3.3 are flagged below — ABCD1 (X-linked adrenoleukodystrophy) and CYP27A1 (cerebrotendinous xanthomatosis) are treatable neurometabolic disorders of particular relevance to neurology, and PLN is a cardiomyopathy gene.

Hereditary cancer

Cardiovascular (cardiomyopathy, arrhythmia, aortopathy, hypercholesterolemia, malignant hyperthermia)

Connective tissue & vascular

Metabolic

Paraganglioma-pheochromocytoma

Ophthalmologic

The reproductive options below are not a menu to be ranked from best to worst — they map onto profoundly different values: how a couple weighs the risk of an affected child, their stance on pregnancy termination, their tolerance for the burden and cost of IVF, and their views on disability itself. The counselor's job is to make the trade-offs visible, then step back. Timing is the one thing that is objectively better earlier: every option except prenatal diagnosis depends on planning before conception.

Carrier screening — knowing the risk before there is a pregnancy

ACMG's 2021 position recommends expanded carrier screening (a standardized ~113-gene panel) for everyone considering pregnancy, regardless of ethnicity. The shift away from ethnicity-based panels is deliberate: self-reported ancestry is a poor proxy for which variants someone carries, and admixture makes targeted panels miss carriers. ACOG (Committee Opinions 690/691) still accepts ethnic-specific, pan-ethnic, and expanded approaches as reasonable. Panels capture SMA, Tay-Sachs, Canavan, the Fragile X premutation, and more. The decisive value of screening is that a couple found to be at risk still has every option open — they learn before there is a pregnancy to make decisions about.

Prenatal diagnosis — definitive, but inside an established pregnancy

• CVS (10–13 weeks) or amniocentesis (15–20 weeks) give a definitive fetal diagnosis at a procedure-related miscarriage risk of roughly 0.1–0.3%. They are the right tool when a couple accepts pregnancy and wants certainty, but they place any decision about an affected fetus in the emotionally and ethically harder context of continuing or ending a wanted pregnancy.

PGT-M — moving the decision before pregnancy begins

Preimplantation genetic testing for monogenic disorders pairs IVF with biopsy of blastocyst-stage embryos so that only unaffected embryos are transferred. Its appeal is precisely that it relocates selection to before implantation, sidestepping prenatal diagnosis and possible termination — which is why it is often the answer for couples who decline the latter. The trade-offs are real: it requires IVF (cost, hormonal stimulation, no guarantee of a viable embryo) and custom probe development (~4–6 weeks) for the family's specific variant. It works for essentially any monogenic condition with a known variant — HD, SMA, TSC, SCN1A.

NIPS — a screen, not a diagnosis, and the distinction is clinically dangerous to blur

Cell-free DNA screening is excellent for common aneuploidies (trisomy 21/18/13). For rare microdeletions like 22q11.2 it is treacherous: because the condition is rare in the population, even a very specific test yields a low positive predictive value, so most positive results are false positives. A positive NIPS for a rare condition is a flag to confirm, never a result to act on — confirmatory CVS or amniocentesis is mandatory before any irreversible decision.

Reproductive autonomy frames all of it. Disability-rights perspectives rightly challenge the unexamined assumption that a genetic condition is something to be prevented, and a non-directive counselor presents that view honestly rather than presuming the couple shares the clinic's defaults. Donor gametes, embryo donation, and adoption round out the options for those who decline to pass on a known variant.

Genomics generates ethical problems faster than guidelines can settle them, because the underlying data are durable, shared, and constantly reinterpreted. A genetic result is not a snapshot that expires — it is a standing claim about a person and their relatives whose meaning changes as knowledge accumulates. Most of the dilemmas below stem from that single property.

Duty to recontact — the result that changes after you've moved on

When a VUS is later reclassified to P/LP (or downgraded to benign), the original report was accurate when issued but may now be wrong in a clinically important way. Beneficence argues for recontacting the patient; logistics argue against a blanket mandate — clinics close, patients move, and the volume of reclassifications is large. No society imposes a universal duty. The defensible middle ground is systematic re-analysis workflows plus honesty at consent that reclassification can happen and that the patient shares responsibility for staying reachable.

Data sharing — a tension between privacy and collective benefit

Variant classification is only as good as the aggregated evidence behind it, and databases like ClinVar and DECIPHER exist because labs contribute. Sharing de-identified data is supported by beneficence: every contributed variant helps resolve someone else's VUS. The cost is privacy and the limits of de-identification, which is why consent should address data-sharing explicitly rather than burying it.

Direct-to-consumer testing — the false-reassurance trap

DTC products (e.g., 23andMe reporting APOE ε4 and a few BRCA founder mutations) test a handful of variants, not whole genes. A negative DTC BRCA result in someone with a strong family history is dangerously misleading — it excludes only the specific founder variants screened, not the hundreds of other pathogenic variants. DTC results are leads to confirm with clinical-grade testing, never a basis for medical decisions.

Equity — inequity built into the reference data

Access is constrained (the US has only ~6,000 certified genetic counselors), but the deeper problem is structural: populations underrepresented in gnomAD and ClinVar receive higher VUS rates, because a variant cannot be confidently called benign or pathogenic without enough same-ancestry data. The result is that the people already least served by genetics get the least interpretable answers — a self-reinforcing inequity that telegenetics widens access to but does not fix; only diversifying the databases does.

Emerging frontiers

• Polygenic risk scores for neuropsychiatric conditions have limited clinical utility and perform poorly across ancestries (they are trained largely on European-ancestry cohorts), raising the twin risks of misleading low-confidence predictions and genetic determinism — treating a probabilistic score as destiny.
• Somatic gene editing is now clinical reality (CRISPR-based therapy for sickle cell disease), correcting cells in one consenting patient. Germline editing, which would alter all descendants who never consented, remains prohibited in most jurisdictions — the bright line being heritability and the inability of future generations to agree.